R&D News | pharmaphorum

News

Keytruda improves survival in early-stage kidney cancer

MSD’s Keytruda has become the first checkpoint inhibitor to show improved survival when used as adjuvant therapy after surgery to remove tumours in clear cell renal cell c

News

BMS' subcutaneous Opdivo clears first phase 3 trial

Bristol-Myers Squibb is getting closer to offering a subcutaneous version of its cancer immunotherapy Opdivo to patients after it matched the current intravenous formulati

News

Then there were two: ArriVent set to list after $175m IPO

ArriVent BioPharma was beaten to the first biotech initial public offering of the year when CG Oncology made its debut on the Nasdaq yesterday, but is due to start trading

News

Ex-Conservative leader William Hague (L) and former Labour Prime Minister Tony Blair (R)

New NHS trust should oversee, sell patient data, says report

Two former political rivals in the UK have joined forces to write a strategy to keep the country at the forefront of the biotech and artificial intelligence sectors – and

News

Synnovation’s $102m round heads latest biotech financings

Momentum seems to be building behind biotech financings as the first month of 2023 draws to a close, with a respectable raise for cancer start-up Synnovation Therapeutics

News

Glenmark licenses cancer drug from China’s Alphamab, 3D Med

India’s Glenmark Pharma has added to its oncology pipeline by licensing rights to a checkpoint inhibitor from China’s Jiangsu Alphamab Biopharmaceuticals and 3D Medicines

Keytruda improves survival in early-stage kidney cancer

BMS' subcutaneous Opdivo clears first phase 3 trial

Then there were two: ArriVent set to list after $175m IPO

New NHS trust should oversee, sell patient data, says report

Synnovation’s $102m round heads latest biotech financings

Glenmark licenses cancer drug from China’s Alphamab, 3D Med

Ethical AI & trust-driven innovation: UCB’s Erik Janssen

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks